Long-term treatment with doxazosin in men with benign prostatic hyperplasia: 10-year follow-up

International Urology and Nephrology

Volumn 36, Issue 2, 2004, Pages 169-173

  Dutkiewicz, Sławomir ^a,b  

^a Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego   (Poland)

^b NONE   (Poland)

Author keywords

Alpha adrenoceptor; Benign prostatic hyperplasia; Doxazosin; Pharmacotherapy

Indexed keywords

DOXAZOSIN;

ADULT; AGED; AMBULATORY CARE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FATIGUE; FOLLOW UP; HEADACHE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE SURGERY; RESIDUAL URINE; RISK ASSESSMENT; TREATMENT OUTCOME; URINE FLOW RATE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; DOXAZOSIN; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA;

EID: 3242676993     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:UROL.0000034688.65087.18     Document Type: Article

References (17)

1. Jacobsen SJ, Jacobsen DJ, Girman CJ, Roberts R, Rhoodes T, Lieber MN. Natural history of prostatism: risk factors acute urinary retention. J Urol 1997; 158: 481-487.
2. Dutkiewicz S. Health of Man. Urinary and Sexual Tract. Warsaw: Amedic, 2002.
3. Macfarlane GJ, Sagnier PP, Richard F, Teillac P, Botto H, Boyle P. Determinants of treatment - seeking behaviour for urinary symptoms in older men. Br J Urol 1995; 76: 714-718.
4. Donovan JL, Kay HE, Peters TJ, Abrams P, Coust J, Matos-Ferriera A, Retzhog L, Bosch JLHR, Nordling J, Gajewski JB, Barbalias G, Schick E, Mendes Silva M, Nisselcorn I, de la Rosette JJMCH. ICS-BPH Study Group: Using the ICSQoL to measure the impact of lower urinary tract symptoms on quality of life: Evidence from the ICS-BPH study. Br J Urol 1997; 80: 712-721.
5. Seagroatt V. Mortality after prostatectomy: Selection and surgical approach. Lancet 1995; 346: 1521-1524.
6. Neal DE. The national prostatectomy audit. Br J Urol 1997; 79 (suppl. 2): 69-75.
7. Dutkiewicz S. Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia. Int Urol Nephrol 2001; 32: 423-432.
8. Dutkiewicz S, Witeska A. Doxazosin - an alpha 1 receptor blocking agent in the long-term management of BPH (part one). Int Urol Nephrol 1995; 27(3): 311-318.
9. Dutkiewicz S, Witeska A, Steȩpień K. Doxazosin - an alpha 1 receptor blocking agent in the long-term management of BPH (part two). Int Urol Nephrol 1995; 27(4): 413-417.
10. Dutkiewicz S. A comparative study of long-term alpha 1-blocker Doxazosin in therapy versus surgery in the treatment of BPH. Mat Med Pol 1995; 27(4): 151-152.
11. Dutkiewicz S. Comparative tolerability of alpha-blockers in the treatment of BPH (including own experience). Mat Med Pol 1998; 31(3-4): 11-19.
12. Dutkiewicz S. Benign Prostatic Hyperplasia. Warsaw: Polish Scientific Publishers PWN, 1994.
13. Cockett ATK, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, Murphy G (ed.). Proceeding 3 - The 3rd International Consultation on Benign Prostatic Hyperplasia (BPH). June 26-28, 1995, Monaco: Scientific Communication International Ltd, 1996.
14. Lepor H, Kaplan SA, Klimberg I, Mobley DF, Fawzy A, Gaffney M, Ice K, Dias N. For the Multicenter Study Group: Doxazosin for benign prostatic hyperplasia: Long-term efficacy and safety in hypertensive and normotensive patients. J Urol 1997; 157: 525-530.
15. Mobley DF, Dias N, Levenstein M. Effects of doxazosin in patients with mild, intermediate and severe benign prostatic hyperplasie. Clin T-her 1998; 20: 101-109.
16. Mobley DF, Kaplan S, Ice K, Gaffney M., Dias N. Effects of doxazosin on the symptoms of benign prostatic hyperplasia. Results from three double blind placebo - control-led studies. Int J Clin Pract 1997; 51: 282-288.
17. Andersen M, Dahlstrand Ch, Hoye K. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasie. Eur Urol 2000; 38: 400-409.